PharmaShots Weekly Snapshots (July 26 – 30, 2021)

 PharmaShots Weekly Snapshots (July 26 – 30, 2021)

Roche Publishes the Results of Evrysdi (risdiplam) in FIREFISH Study to Treat of Type 1 SMA at NEJM

Published: July 30, 2021 | Tags: Roche, Evrysdi, risdiplam, FIREFISH Study, Type 1 SMA, NEJM

BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III SEQUOIA Trial for the Treatment of Chronic Lymphocytic Leukemia

Published: July 30, 2021 | Tags: BeiGene, Brukinsa, zanubrutinib, P-III, SEQUOIA Trial, Chronic Lymphocytic Leukemia

Alnylam Signs a License Agreement with PeptiDream to Develop and Commercialize Peptide-siRNA Conjugates for Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues

Published: July 30, 2021 | Tags: Alnylam, PeptiDream, Peptide-siRNA Conjugates, RNAi Therapeutics, Extrahepatic Tissues

Junshi Reports NMPA’s Acceptance of sNDA for Toripalimab + CT as 1L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Published: July 30, 2021 | Tags: Junshi, NMPA, Acceptance, sNDA, Toripalimab, CT, Advanced, Metastatic, Esophageal Squamous Cell Carcinoma

GSK’s Nucala (mepolizumab) Receives the US FDA’s Approval for the Treatment of Chronic Rhinosinusitis with Nasal Polyps

Published: July 30, 2021 | Tags: GSK, Nucala, mepolizumab, US, FDA, Chronic Rhinosinusitis, Nasal Polyps

Lilly Collaborates with Kumquat to Develop Novel Small Molecules that Enhance Tumor-Specific Immune Responses

Published: July 30, 2021 | Tags: Lilly, Kumquat, Novel Small Molecules, Tumor-Specific Immune Responses

Takeda’s TAK-994 Receives Breakthrough Therapy Designation for the Treatment of Narcolepsy Type 1

Published: July 29, 2021 | Tags: Takeda, TAK-994, Breakthrough Therapy Designation, Narcolepsy Type

Janssen Amends its Agreement with Protagonist to Develop and Commercialize IL-23 Antagonists

Published: July 29, 2021 | Tags: Protagonist, Amendment Agreement, Janssen, IL-23 Antagonists

Viatris and Biocon’s Semglee (biosimilar, insulin glargine) Receive the US FDA’s Approval as the First Interchangeable Biosimilar for Diabetes

Published: July 29, 2021 | Tags: Viatris, Biocon, Semglee, biosimilar, Insulin Glargine, US, FDA, Approval, Diabetes

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III LIBERTY CUPID Clinical Program for Chronic Spontaneous Urticaria

Published: July 29, 2021 | Tags: Regeneron, Sanofi, Dupixent, dupilumab, P-III, LIBERTY CUPID Clinical Program, Chronic Spontaneous Urticaria

Roche Reports the US FDA’s Acceptance of BLA for Faricimab to Treat Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration

Published: July 29, 2021 | Tags: Roche, US, FDA, Acceptance, BLA, Faricimab, Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration

BD Acquires Tepha to Boost its Surgical Mesh Portfolio

Published: July 29, 2021 | Tags: BD, Tepha, Surgical Mesh Portfolio

Arena and Aristea Collaborate to Develop RIST4721 for Treatment of Complicated Immune-Mediated Inflammatory Diseases

Published: July 28, 2021 | Tags: Arena, Aristea, RIST4721, Immune-Mediated Inflammatory Diseases

BridgeBio Enters into Clinical Collaboration with BMS to Evaluate BBP-398 + Opdivo for Advanced Solid Tumors with KRAS Mutations

Published: July 28, 2021 | Tags: BridgeBio, BMS, BBP-398, Opdivo, Advanced Solid Tumors, KRAS Mutations

Sanofi’s Avalglucosidase alfa Receives CHMP’s Positive Opinion for Patients with Pompe Disease

Published: July 28, 2021 | Tags: Sanofi, Avalglucosidase alfa, CHMP, Pompe Disease

AbbVie and Calico Expand its Existing Collaboration to Focus on Aging and Age-Related Diseases

Published: July 28, 2021 | Tags: AbbVie, Calico, Age-Related Diseases

PeptiDream and Takeda Expand its Research and License Agreement to Develop Peptide Drug Conjugates Targeting CNS Diseases

Published: July 28, 2021 | Tags: PeptiDream, Takeda, Peptide Drug Conjugates, CNS Diseases

Amgen to Acquire Teneobio for ~$2.5B

Published: July 28, 2021 | Tags: Amgen, Acquire, Teneobio, ~$2.5B

AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies for Obesity

Published: July 27, 2021 | Tags: AstraZeneca, Regeneron, Develop, Commercialize, Therapies, Obesity

BioNTech Plans to Initiate the Clinical Study of Malaria and Tuberculosis Vaccines in 2022

Published: July 27, 2021 | Tags: BioNTech, Malaria, Tuberculosis Vaccines, 2022

Adagio Collaborates with Biocon to Provide COVID-19 Ab Treatment to Patients in India and Other Emerging Markets

Published: July 27, 2021 | Tags: Adagio, Biocon, COVID-19 Ab

GSK’s Shingrix Receives the US FDA’s Approval to Prevent Shingles in Immunocompromised Adults

Published: July 27, 2021 | Tags: GSK, Shingrix, US, FDA, Approval, Shingles, Immunocompromised

Prothena Presents Preclinical Data of its Alzheimer’s Candidates at AAIC 2021

Published: July 27, 2021 | Tags: Prothena, Preclinical Data, Alzheimer Candidates, AAIC 2021

BeiGene’s Brukinsa (Zanubrutinib) Receives Health Canada’s Approval for Mantle Cell Lymphoma

Published: July 27, 2021 | Tags: BeiGene, Brukinsa, Zanubrutinib, Health Canada, Approval, Mantle Cell Lymphoma

PerkinElmer to Acquire BioLegend for $5.25B

Published: July 26, 2021 | Tags: PerkinElmer, Acquire, BioLegend, $5.25B

Denali Reports Results of DNL310 in P-I/II Study in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)

Published: July 26, 2021 | Tags: Denali, DNL310, P-I/II, Study, Lysosomal Storage Disease Hunter Syndrome, MPS II

The US FDA Declines to Approve Incyte’s Retifanlimab to Treat Patients with Squamous Cell Carcinoma of the Anal Canal

Published: July 26, 2021 | Tags: US, FDA, Incyte, Retifanlimab, Squamous Cell Carcinoma, Anal Canal

AbbVie Presents Results of AGN-190584 in P-III GEMINI 1 Study for Presbyopia at 2021 ASCRS

Published: July 26, 2021 | Tags: AbbVie, AGN-190584, P-III, GEMINI 1 Study, Presbyopia, 2021 ASCRS

Alexion’s Ultomiris (ravulizumab) Receives CHMP’s Positive Opinion Recommending its Approval for Children and Adolescents with PNH

Published: July 26, 2021 | Tags: Alexion, Ultomiris, ravulizumab, CHMP, PNH

AstraZeneca’s Vaxzevria Demonstrates Effectiveness After One Dose Against Beta/Gamma and Delta Variants of SARS-CoV-2 Virus

Published: July 26, 2021 | Tags: AstraZeneca, Vaxzevria, Delta Variants, SARS-CoV-2 Virus

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post